CTLA4 and fibrosarcoma: In a mouse model of fibrosarcoma, treatment with immune checkpoint inhibitors, (anti-PD-1 and -CTLA-4) induced the frequency and maturation of TA-HEVs and led to increased numbers of infiltrating CD4 and CD8 T cells (60).